이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Spectrum Pharmaceuticals 관리

관리 기준 확인 1/4

Spectrum Pharmaceuticals' CEO는 Tom Riga, Dec2021 에 임명되었습니다 의 임기는 1.67 년입니다. 총 연간 보상은 $ 2.60M, 25% 로 구성됩니다. 25% 급여 및 75% 보너스(회사 주식 및 옵션 포함). 는 $ 537.60K 가치에 해당하는 회사 주식의 0.26% 직접 소유합니다. 537.60K. 경영진과 이사회의 평균 재임 기간은 각각 1.5 년과 2.5 년입니다.

주요 정보

Tom Riga

최고 경영자

US$2.6m

총 보상

CEO 급여 비율	25.0%
CEO 임기	1.7yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	2.5yrs

최근 관리 업데이트

Recent updates

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

May 14

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

May 12

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Sep 20

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Sep 16

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Sep 09

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Aug 21

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Jun 04

Spectrum Pharmaceuticals: Some Last Words

Feb 25

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Oct 05

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

May 31

We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate

Feb 12

Spectrum Pharma drops after announcing less-than-favorable Phase 2 data

Dec 22

Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like

Dec 21

Spectrum Pharma Is Down But Not Out

Nov 16

Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib

Nov 11

CEO 보상 분석

Tom Riga 의 보수는 Spectrum Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$3m	US$650k	-US$78m
Sep 30 2022	n/a	n/a	-US$106m
Jun 30 2022	n/a	n/a	-US$117m
Mar 31 2022	n/a	n/a	-US$138m
Dec 31 2021	US$4m	US$550k	-US$158m
Sep 30 2021	n/a	n/a	-US$169m
Jun 30 2021	n/a	n/a	-US$184m
Mar 31 2021	n/a	n/a	-US$166m
Dec 31 2020	US$3m	US$550k	-US$171m
Sep 30 2020	n/a	n/a	-US$162m
Jun 30 2020	n/a	n/a	-US$140m
Mar 31 2020	n/a	n/a	-US$136m
Dec 31 2019	US$4m	US$550k	-US$135m
Sep 30 2019	n/a	n/a	-US$148m
Jun 30 2019	n/a	n/a	-US$191m
Mar 31 2019	n/a	n/a	-US$147m
Dec 31 2018	US$5m	US$500k	-US$127m
Sep 30 2018	n/a	n/a	-US$102m
Jun 30 2018	n/a	n/a	-US$51m
Mar 31 2018	n/a	n/a	-US$87m
Dec 31 2017	US$1m	US$420k	-US$101m

보상 대 시장: Tom 의 총 보상 ($USD 2.60M )은 US 시장( $USD 1.62M ).

보상과 수익: Tom 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Tom Riga (48 yo)

1.7yrs

테뉴어

US$2,595,633

보상

Mr. Thomas J. Riga, also known as Tom, is President, Chief Executive Officer and Director at Spectrum Pharmaceuticals, Inc. since December 30, 2021. He had been the Chief Operating Officer at Spectrum Phar...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Riga	President	1.7yrs	US$2.60m	0.26% $ 537.6k
Nora Brennan	Executive VP & CFO	1.3yrs	US$46.25k	0.051% $ 108.0k
Keith McGahan	Executive VP	5.5yrs	US$1.50m	0.11% $ 239.2k
Michael Grabow	Executive VP & Chief Business Officer	less than a year	데이터 없음	데이터 없음

1.5yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: SPPI 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Riga	President	1.7yrs	US$2.60m	0.26% $ 537.6k
Seth H. Fischer	Independent Director	3.3yrs	US$178.83k	0.0020% $ 4.2k
William Ashton	Independent Chairman of the Board	5.5yrs	US$202.58k	0.021% $ 43.9k
Jeffrey Vacirca	Independent Director	4.8yrs	US$181.33k	0.13% $ 278.4k
Brittany Bradrick	Independent Director	1.3yrs	US$158.53k	데이터 없음
Juhyun Lim	Director	1.4yrs	US$183.93k	0.0023% $ 4.9k

2.5yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 이사회: SPPI 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Spectrum Pharmaceuticals 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

President notifies of intention to sell stock

Spectrum Pharmaceuticals Announces Executive Changes

Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to its Board of Directors

Spectrum Pharmaceuticals, Inc. Announces Resignation of Kurt Gustafson as Chief Financial Officer

High number of new directors

Recent updates

Spectrum Pharmaceuticals, Inc. Files Form 15

Spectrum Pharmaceuticals, Inc.(NasdaqCM:SPPI) dropped from NASDAQ Composite Index

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus estimates of losses per share improve by 38%

Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts

Price target decreased by 33% to US$1.26

Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.17 loss

Price target decreased by 15% to US$2.65

Spectrum Pharmaceuticals, Inc. Receives Permanent J-Code for ROLVEDON Injection (J1449) from U.S. Centers for Medicare & Medicaid Services

President notifies of intention to sell stock

Consensus revenue estimates increase by 161%

Spectrum Pharmaceuticals, Inc. Provides Sales Guidance for the Quarter Ended December 31, 2022

Spectrum Pharmaceuticals Announces Executive Changes

Forecast to breakeven in 2025

Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Spectrum Pharmaceuticals, Inc

Spectrum Pharmaceuticals’ ROLVEDON™ Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors

Consensus revenue estimates increase by 16%

Spectrum Pharmaceuticals, Inc. Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection

Price target decreased to US$3.10

Price target decreased to US$4.13

Spectrum Pharmaceuticals Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Spectrum Pharmaceuticals Announces Commercial Availability of Rolvedon™ (Eflapegrastim-Xnst) Injection

No longer forecast to breakeven

Spectrum Pharmaceuticals, Inc. Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Price target decreased to US$5.40

Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC

Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?

Consensus forecasts updated

Spectrum Pharmaceuticals Receives Food and Drug Administration Approval for ROLVEDON (eflapegrastim-xnst) Injection

Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection

Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'

Consensus revenue estimates fall by 61%

Spectrum Pharmaceuticals Q2 2022 Earnings Preview

Spectrum Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Consensus forecasts updated

Spectrum Pharmaceuticals, Inc. Appoints Nora E. Brennan as Chief Financial Officer

Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to its Board of Directors

Price target decreased to US$5.60

Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

Price target decreased to US$5.60

Spectrum Pharmaceuticals: Some Last Words

Spectrum Pharmaceuticals, Inc. Announces Resignation of Kurt Gustafson as Chief Financial Officer

Spectrum Pharmaceuticals, Inc. Announces Acceptance of New Drug Application Filing for Poziotinib

Spectrum Pharmaceuticals Announces Strategic Restructuring

Forecast to breakeven in 2024

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Spectrum Pharmaceuticals, Inc. Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at European Society for Medical Oncology Congress 2021

Pomerantz LLP Announces the Filing of Class Action Against Spectrum Pharmaceuticals, Inc and Certain Officers

Consensus revenue estimates fall to US$2.30m

Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity

Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for ROLONTIS® (eflapegrastim)

No longer forecast to breakeven

Price target decreased to US$9.40

High number of new directors

Spectrum's Big Approval: Any Day Now

Spectrum Pharmaceuticals, Inc.(NasdaqGS:SPPI) dropped from Russell 3000E Value Index

Consensus revenue estimates fall to US$20.0m

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the Zenith20 Clinical Trial

Spectrum Pharmaceuticals Announces Initiation of Pre-Approval Inspection for ROLONTIS®

FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS

Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation

Forecast breakeven pushed back to 2024

Consensus forecasts updated

FDA Grants Fast Track Designation to Spectrum Pharmaceuticals, Inc.'s Poziotinib